oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes trial New Science Suggests Improves CV Beyond Weight Loss Semaglutide cardiovascular outcomes – Canadian Perspectives 2025 Whiteboard on

Clinical Research Findings: SUSTAIN and PIONEER Trials A comprehensive safety analysis of 11,159 patients with type 2 diabetes across the SUSTAIN and PIONEER phase IIIa clinical trial programs found that gastrointestinal disorders occurred in 41.9% of patients receiving subcutaneous semaglutide and 39.1% receiving oral semaglutide, compared to 22.0% and 24.8% in comparator groups, respectively

Peptide Calculator The Retatrutide peptide calculator is a versatile research tool built to simplify peptide math

Elevated GH secretion drives downstream IGF-1 production, mediated primarily through hepatic GH receptor signalling, and the GH/IGF-1 axis effects of ipamorelin including anabolic signalling in skeletal muscle, lipolytic activity in adipose tissue, and effects on bone metabolism have been studied in multiple preclinical models

~ Chrystal